-
Trevena's 30% Plunge, Explained
Tuesday, February 21, 2017 - 9:48am | 414Read More...Trevena Inc (NASDAQ: TRVN), a clinical-stage biopharmaceutical company that focuses on therapeutics that use an approach to target G protein coupled receptors (GPCRs), saw its shares plummet around 30 percent Tuesday morning despite a positive development in Phase 3 trials. Trevena announced...
-
Importance Of Phase 2 Trials
Monday, July 25, 2016 - 8:14am | 515Read More...Healthcare and pharmaceutical companies begin evaluating a drug they wish to sell to the public through a series of clinical trials. A Phase I trial consists of a company testing its drug or therapy on a small group of 20 to 100 healthy volunteers. Chiara Russo, a stock analyst for Cantor...
